贲门失弛缓症 中国就医指南

Achalasia is a rare primary esophageal motility disorder characterized by the failure of the lower esophageal sphincter (LES) to relax adequately during swallowing, coupled with absent or ineffective peristalsis in the distal two-thirds of the esophageal body. This functional obstruction leads to progressive dysphagia (initially for solids, later for liquids), regurgitation of undigested food, retrosternal discomfort, and weight loss. Pathophysiologically, achalasia results from degeneration and loss of inhibitory ganglion cells—particularly nitric oxide synthase (NOS)- and vasoactive intestinal peptide (VIP)-expressing neurons—in the myenteric plexus of the esophagus. The exact etiology remains unclear but is thought to involve autoimmune, viral (e.g., herpes simplex virus-1, measles), and genetic components, with growing evidence of chronic inflammatory infiltration and neuronal apoptosis. Epidemiologically, achalasia affects approximately 1–1.6 per 100,000 individuals annually worldwide, with a prevalence of 10–12 per 100,000. It occurs equally across sexes and most commonly presents between ages 25 and 60, though pediatric and geriatric cases are documented. No definitive environmental or lifestyle risk factors have been established; however, familial clustering and associations with certain HLA haplotypes (e.g., HLA-DQB1*05:01) suggest a genetic predisposition. Autoimmune comorbidities—including type 1 diabetes, Sjögren’s syndrome, and thyroid disease—are observed more frequently than in the general population. Quality of life is significantly impaired: patients report chronic fatigue, social withdrawal due to meal-related anxiety and embarrassment, sleep disruption from nocturnal regurgitation and aspiration, and heightened risk of aspiration pneumonia and esophageal squamous cell carcinoma (with lifetime risk estimated at 2–7%). Untreated, symptoms worsen progressively, leading to esophageal dilation (megaesophagus), stasis, and structural remodeling. Early diagnosis—via high-resolution manometry (HRM), barium esophagram, and upper endoscopy—is critical to guide appropriate intervention and prevent irreversible esophageal damage.

# 贲门失弛缓症治疗方案与费用明细（消化内科）

一、非手术/保守治疗

适用人群：早期轻症、高龄、合并严重基础病无法耐受操作者

• •药物治疗：硝酸酯类（单硝酸异山梨酯）、钙通道阻滞剂（地尔硫䓬）；月均药费 80–300元
• •内镜下球囊扩张（短期缓解）：含术前胃镜+食管测压+钡餐，总费用 4,200–6,500元（含检查费1,800元）
• •理疗辅助：吞咽功能训练、饮食行为干预（三甲医院康复科协作），单疗程（4周） 1,200–2,000元

二、手术/微创介入治疗

首选方案：经口内镜下肌切开术（POEM）

• •适应证：中重度症状、药物无效、无严重食管扩张或癌变证据
• •全套费用：术前检查（胃镜+高分辨率食管测压+食管造影+心肺评估）2,600–3,500元；POEM手术（含麻醉、耗材、住院7天）38,000–52,000元

三、特殊复杂情况处理

• •食管显著扩张（>6 cm）或合并Barrett食管：需联合抗反流手术（如Heller+Dor），总费用 65,000–88,000元
• •术后复发/难治性病例：重复POEM或转开放肌切开，费用上浮20%–30%

四、方案快速选择指南

✅ 预算≤5,000元/年：优选药物+生活方式管理 ✅ 追求根治且预算4万–5万元：首选POEM（三甲医院标准路径） ✅ 高龄/多系统衰竭：球囊扩张+营养支持（总控费≤7,000元） ✅ 合并重度食管炎或可疑癌变：须先行活检及肿瘤评估，再定手术策略